These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25608470)

  • 1. HIV tropism shift: new paradigm on cell therapy strategies for HIV cure.
    Poveda E
    AIDS Rev; 2015; 17(1):65. PubMed ID: 25608470
    [No Abstract]   [Full Text] [Related]  

  • 2. Shift of HIV tropism in stem-cell transplantation with CCR5 Delta32 mutation.
    Kordelas L; Verheyen J; Beelen DW; Horn PA; Heinold A; Kaiser R; Trenschel R; Schadendorf D; Dittmer U; Esser S;
    N Engl J Med; 2014 Aug; 371(9):880-2. PubMed ID: 25162903
    [No Abstract]   [Full Text] [Related]  

  • 3. European guidelines on the clinical management of HIV-1 tropism testing.
    Vandekerckhove LP; Wensing AM; Kaiser R; Brun-Vézinet F; Clotet B; De Luca A; Dressler S; Garcia F; Geretti AM; Klimkait T; Korn K; Masquelier B; Perno CF; Schapiro JM; Soriano V; Sönnerborg A; Vandamme AM; Verhofstede C; Walter H; Zazzi M; Boucher CA;
    Lancet Infect Dis; 2011 May; 11(5):394-407. PubMed ID: 21429803
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 co-receptor usage based on V3 loop sequence analysis: preferential suppression of CXCR4 virus post HAART?
    Jiao Y; Wang P; Zhang H; Zhang T; Zhang Y; Zhu H; Wu H
    Immunol Invest; 2011; 40(6):597-613. PubMed ID: 21513481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transmission of the X4 phenotype of HIV-1: is there evidence against the "random transmission" hypothesis?
    Hedskog C; Mild M; Albert J
    J Infect Dis; 2012 Jan; 205(2):163-5. PubMed ID: 22147793
    [No Abstract]   [Full Text] [Related]  

  • 6. Tropism switch in patients infected with HIV-1 and its clinical implications for the treatment with CCR5-receptor inhibitors.
    Arastéh K; Stocker H
    Eur J Med Res; 2007 Oct; 12(9):397-402. PubMed ID: 17933720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Seeking a cure for AIDS.
    Laurence J
    AIDS Read; 2008 May; 18(5):228, 234. PubMed ID: 18589476
    [No Abstract]   [Full Text] [Related]  

  • 8. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism.
    González N; Pérez-Olmeda M; Mateos E; Cascajero A; Alvarez A; Spijkers S; García-Pérez J; Sánchez-Palomino S; Ruiz-Mateos E; Leal M; Alcami J
    J Antimicrob Chemother; 2010 Dec; 65(12):2493-501. PubMed ID: 20947622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of HIV tropism and its use in the clinical practice.
    Pérez-Olmeda M; Alcami J
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1291-302. PubMed ID: 24191978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maraviroc treatment in non-R5-HIV-1-infected patients results in the selection of extreme CXCR4-using variants with limited effect on the total viral setpoint.
    McGovern RA; Symons J; Poon AF; Harrigan PR; van Lelyveld SF; Hoepelman AI; van Ham PM; Dong W; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2013 Sep; 68(9):2007-14. PubMed ID: 23677920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in HIV-1 tropism: clinical and prognostic consequences.
    Mosier DE
    Eur J Med Res; 2007 Oct; 12(9):371-4. PubMed ID: 17933716
    [No Abstract]   [Full Text] [Related]  

  • 12. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression.
    Raymond S; Delobel P; Mavigner M; Cazabat M; Encinas S; Souyris C; Bruel P; Sandres-Sauné K; Marchou B; Massip P; Izopet J
    AIDS; 2010 Sep; 24(15):2305-12. PubMed ID: 20808203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.
    van der Ryst E; Heera J; Demarest J; Knirsch C
    Ann N Y Acad Sci; 2015 Jun; 1346(1):7-17. PubMed ID: 25962411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 X4/R5 co-receptor in viral reservoir during suppressive HAART.
    Soulié C; Marcelin AG; Ghosn J; Amellal B; Assoumou L; Lambert S; Duvivier C; Costagliola D; Katlama C; Calvez V
    AIDS; 2007 Oct; 21(16):2243-5. PubMed ID: 18090053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More on the treatment-tropism relationship: the impact of prior antiretroviral treatment on HIV coreceptor tropism among subjects entering AIDS clinical trials group 175.
    Shulman NS; Kassaye SG; Winters MA; Johnston E; Katzenstein DA
    J Infect Dis; 2007 Jul; 196(2):328-9; author reply 329-30. PubMed ID: 17570122
    [No Abstract]   [Full Text] [Related]  

  • 16. When and how to use maraviroc in HIV-infected patients.
    Soriano V; Perno CF; Kaiser R; Calvez V; Gatell JM; di Perri G; Pillay D; Rockstroh J; Geretti AM
    AIDS; 2009 Nov; 23(18):2377-85. PubMed ID: 19834318
    [No Abstract]   [Full Text] [Related]  

  • 17. New HIV drug classes on the horizon.
    Opar A
    Nat Rev Drug Discov; 2007 Apr; 6(4):258-9. PubMed ID: 17457997
    [No Abstract]   [Full Text] [Related]  

  • 18. Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
    Soulié C; Fourati S; Lambert-Niclot S; Malet I; Wirden M; Tubiana R; Valantin MA; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2010 Apr; 65(4):749-51. PubMed ID: 20150182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Originality of entry inhibitors].
    Izopet J
    Med Mal Infect; 2009 Oct; 39(10 Suppl 1):H1-4. PubMed ID: 19837343
    [No Abstract]   [Full Text] [Related]  

  • 20. Change in HIV-1 DNA tropism despite virological success in patients receiving an enfuvirtide-based regimen.
    Charpentier C; Joly V; Ghosn J; Yeni P; Raffi F; Descamps D; Morand-Joubert L
    J Antimicrob Chemother; 2014 Sep; 69(9):2588-90. PubMed ID: 24816213
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.